Reporting of studies on new medicines in major medical journals: A case study in breast cancer

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 398-400

  Vitry, A I ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; LAPATINIB; PACLITAXEL; ROFECOXIB;

ADVANCED CANCER; BREAST CANCER; CANCER GROWTH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SHORT SURVEY; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PACLITAXEL; PERIODICALS AS TOPIC; QUINAZOLINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77949817310     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.278     Document Type: Short Survey

References (15)

1. Chan, A.W., Hrobjartsson, A., Haahr, M.T., Gotzsche, P.C. & Altman, D.G. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291, 2457-2465 (2004).
2. Turner, E.H., Matthews, A.M., Linardatos, E., Tell, R.A. & Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358, 252-260 (2008).
3. Juni, P., Rutjes, A.W. & Dieppe, P.A. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324, 1287-1288 (2002).
4. Curfman, G.D., Morrissey, S. & Drazen, J.M. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N. Engl. J. Med. 2000;343:1520-8 [comment]. N. Engl. J. Med. 353, 2813-2814 (2005).
5. US Food and Drug Administration, Center for Drug Evaluation and Research. Tykerb (Lapatinib) Tablets [Drug Approval Package]. http://www.accessdata.fda. gov/drugsatfda- docs/nda/2007/022059s000TOC.cfm (2007).
6. US Food and Drug Administration, Center for Drug Evaluation and Research. Abraxane (Pcalitaxel Protein-Bound Particles) Injectable Suspension [Drug Approval Package]. http:// www.accessdata.fda.gov/drugsatfda-docs/ nda/2005/21660-AbraxaneTOC.cfm (2005).
7. US Food and Drug Administration, Center for Drug Evaluation and Research. BLA STN 125085/91.018 Avastin® (bevacizumab) [FDA Briefing Document: Oncology Drug Advisory Committee Meeting]. http://www.fda.gov/ ohrms/dockets/ac/07/briefing/2007-4332b1-01-FDA.pdf (2007).
8. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
9. Geyer, C.E., Forster, J., Lindquist, D., Chan, S., Romieu, C.G., Pienkowski, T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. Med. 355, 2733-2743 (2006).
10. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005).
11. Trotta, F., Apolone, G., Garattini, S. & Tafuri, G. Stopping a trial early in oncology: for patients or for industry? Ann. Oncol. 19, 1347-1353 (2008).
12. Rising, K., Bacchetti, P. & Bero, L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 5, e217; discussion e (2008).
13. Vitry, A., Lexchin, J., Sasich, L., Dupin-Spriet, T., Reed, T., Bertele, V. et al. Provision of information on regulatory authorities' websites. Intern. Med. J. 38, 559-567 (2008).
14. Wood, A.J. Progress and deficiencies in the registration of clinical trials. N. Engl. J. Med. 360, 824-830 (2009).
15. Smith, R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2, e138 (2005).